Hamlet BioPharma AB publ (FRA:7ZT) ROC %: -179.96% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:7ZT Hamlet BioPharma AB publ FRA:7ZT
31 GF Score
Price €0.58
! 2 Warning Signs
View Full Analysis

What is Hamlet BioPharma AB publ ROC %?

Hamlet BioPharma AB publ FRA:7ZT -2.04% 31 ROC % is -179.96% as of Mar. 2026. GuruFocus rates FRA:7ZT with a GF Score™ of 31/100. The stock has 2 warning signs investors should review.

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Hamlet BioPharma AB publ's annualized return on capital (ROC %) for the quarter that ended in Mar. 2026 was -179.96%.

As of today (2026-08-18), Hamlet BioPharma AB publ's WACC % is 7.08%. Hamlet BioPharma AB publ's ROC % is -181.95% (calculated using TTM income statement data). Hamlet BioPharma AB publ earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Hamlet BioPharma AB publ  (FRA:7ZT) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Hamlet BioPharma AB publ's WACC % is 7.08%. Hamlet BioPharma AB publ's ROC % is -181.95% (calculated using TTM income statement data). Hamlet BioPharma AB publ earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Hamlet BioPharma AB publ ROC % Related Terms

Hamlet BioPharma AB publ ROC % Historical Data

* Premium members only.

The historical data trend for Hamlet BioPharma AB publ's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hamlet BioPharma AB publ ROC % Chart

Hamlet BioPharma AB publ Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -149.75 -305.97 -294.56 -153.39 -141.29

Hamlet BioPharma AB publ Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -133.92 -195.12 -145.95 -209.43 -179.96
FRA:7ZT
31GF Score
Hamlet BioPharma AB publ FRA:7ZT
ROC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hamlet BioPharma AB publ ROC % Calculation

Hamlet BioPharma AB publ's annualized Return on Capital (ROC %) for the fiscal year that ended in Jun. 2025 is calculated as:

ROC % (A: Jun. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Jun. 2024 ) + Invested Capital (A: Jun. 2025 ))/ count )
=-5.006 * ( 1 - 0% )/( (3.903 + 3.183)/ 2 )
=-5.006/3.543
=-141.29 %

where

Invested Capital(A: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=6.074 - 0.125 - ( 2.046 - max(0, 0.364 - 2.418+2.046))
=3.903

Invested Capital(A: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3.958 - 0.277 - ( 0.977 - max(0, 0.66 - 1.158+0.977))
=3.183

Hamlet BioPharma AB publ's annualized Return on Capital (ROC %) for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-4.5 * ( 1 - 0% )/( (2.596 + 2.405)/ 2 )
=-4.5/2.5005
=-179.96 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4.246 - 0.499 - ( 1.529 - max(0, 0.697 - 1.848+1.529))
=2.596

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3.832 - 0.31 - ( 1.303 - max(0, 0.529 - 1.646+1.303))
=2.405

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROC % →
What does a ROC % of -179.96% mean?
Hamlet BioPharma AB publ (FRA:7ZT) has a ROC % of -179.96% as of Mar. 2026. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Hamlet BioPharma AB publ and its competitors.
Is Hamlet BioPharma AB publ's ROC % too high?
Hamlet BioPharma AB publ's current ROC % is -179.96%. Overall, Hamlet BioPharma AB publ has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Hamlet BioPharma AB publ's ROC % compare to VRTX and REGN?
Hamlet BioPharma AB publ's ROC % of -179.96% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC % for a Biotechnology company?
A good ROC % depends on the Biotechnology industry context. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC % mean?
A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Hamlet BioPharma AB publ and its competitors. Hamlet BioPharma AB publ's current ROC % is -179.96%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hamlet BioPharma AB publ stock overvalued right now?
Hamlet BioPharma AB publ (FRA:7ZT) has a current ROC % of -179.96%. The current ROC % is -179.96%. Hamlet BioPharma AB publ's overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC % calculated?
ROC % is calculated from a company's financial statements. For Hamlet BioPharma AB publ (FRA:7ZT), the current ROC % is -179.96% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Hamlet BioPharma AB publ Business Description

Other Exchanges HAMLET B:Sweden
Address Klinikgatan 32, BMC D10, Lund, SWE, SE-222 42
Hamlet BioPharma AB publ is a pharmaceutical company engaged in the research and development of drugs used for curing cancer.
31GF Score

Get the complete analysis for FRA:7ZT

ROC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.58
Price